Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.
Tag Archive for: Antibiotic
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.